Reata Pharmaceuticals (RETA) announced that at a special meeting held today, preliminary results indicate that the stockholders of the company voted to approve the company’s previously announced acquisition by Biogen (BIIB). The expected closing date of the merger is September 26, the company stated. “We are pleased to announce that our stockholders have approved our acquisition by Biogen. This marks a significant milestone in Reata’s journey, and I thank our stockholders for their strong support. We believe the acquisition by Biogen will significantly advance Reata’s vision of developing and delivering novel therapies to patients with rare diseases,” said Warren Huff, Chairman and CEO at Reata.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RETA:
- Reata says waiting period related to merger under Hart-Scott-Rodino act expired
- Sanofi was second bidder for Reata, Bloomberg reports
- RETA Earnings this Week: How Will it Perform?
- Reata Pharmaceuticals downgraded to Neutral from Buy at Citi
- Reata Pharmaceuticals downgraded to Equal Weight from Overweight at Barclays
